Payment overview · 2025
General Payments
$1,080.01
59 reported records · 25 companies
Healthcare provider profile · identity verified
William Benjamin Hundley, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DOTHAN, AL · NPI 1407149511
Verified facts
What the public records show
CMS Open Payments records show William Benjamin Hundley, M.D. received $1,080.01 in general payments during 2025 across 59 reported records.
Abbott Laboratories accounted for 13.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $150.34 | 13.9% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $114.16 | 10.6% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $86.79 | 8.0% | 5 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $67.98 | 6.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $64.78 | 6.0% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $62.44 | 5.8% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $56.65 | 5.2% | 3 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $50.31 | 4.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $49.84 | 4.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $43.76 | 4.0% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $40.17 | 3.7% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $35.16 | 3.3% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$34.13 | 3.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30.92 | 2.9% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $23.65 | 2.2% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $20.60 | 1.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.28 | 1.8% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $18.26 | 1.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.00 | 1.7% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $17.86 | 1.6% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $17.80 | 1.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.97 | 1.6% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.74 | 1.6% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $14.52 | 1.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $8.90 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,080.01 | 59 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $150.34 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $96.80 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $68.46 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $68.46 | 4 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $67.98 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $62.44 | 4 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $50.31 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $49.84 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $40.17 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $37.59 | 2 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $34.13 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $30.92 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $27.22 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $27.22 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $8.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 66 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 70 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 84 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
66 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
84 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
165 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
107 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 646 | 186 |
| Atorvastatin Calcium | Atorvastatin Calcium | 575 | 181 |
| Levothyroxine Sodium | Levothyroxine Sodium | 536 | 149 |
| Pantoprazole Sodium | Pantoprazole Sodium | 430 | 143 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 410 | 142 |
| Lisinopril | Lisinopril | 385 | 111 |
| Gabapentin | Gabapentin | 314 | 88 |
| Losartan Potassium | Losartan Potassium | 311 | 88 |
| Tramadol Hcl | Tramadol Hcl | 272 | 46 |
| Omeprazole | Omeprazole | 271 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 217 | 61 |
| Trazodone Hcl | Trazodone Hcl | 215 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 204 | 61 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 201 | 40 |
| Montelukast Sodium | Montelukast Sodium | 191 | 69 |
| Escitalopram Oxalate | Escitalopram Oxalate | 190 | 64 |
| Meloxicam | Meloxicam | 166 | 55 |
| Metformin Hcl | Metformin Hcl | 165 | 58 |
| Ozempic | Semaglutide | 165 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 164 | 52 |
| Metformin Hcl Er | Metformin Hcl | 164 | 53 |
| Potassium Chloride | Potassium Chloride | 155 | 43 |
| Furosemide | Furosemide | 151 | 48 |
| Donepezil Hcl | Donepezil Hcl | 136 | 45 |
| Alprazolam | Alprazolam | 132 | 28 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 127 | 42 |
| Sertraline Hcl | Sertraline Hcl | 125 | 39 |
| Carvedilol | Carvedilol | 124 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 124 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 122 | 55 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 120 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 118 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 113 | 35 |
| Eliquis | Apixaban | 107 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 101 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 93 | 21 |
| Bupropion Xl | Bupropion Hcl | 88 | 23 |
| Simvastatin | Simvastatin | 88 | 27 |
| Allopurinol | Allopurinol | 85 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 84 | 26 |
| Mounjaro | Tirzepatide | 84 | 18 |
| Buspirone Hcl | Buspirone Hcl | 76 | 23 |
| Temazepam | Temazepam | 75 | 14 |
| Pregabalin | Pregabalin | 72 | 19 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 71 | 71 |
| Jardiance | Empagliflozin | 70 | 16 |
| Farxiga | Dapagliflozin Propanediol | 66 | 20 |
| Celecoxib | Celecoxib | 62 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 23 |
| Myrbetriq | Mirabegron | 61 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 61 | 16 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 61 | 54 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | 11 |
| Alendronate Sodium | Alendronate Sodium | 59 | 14 |
| Clonidine Hcl | Clonidine Hcl | 58 | 20 |
| Ondansetron Odt | Ondansetron | 57 | 33 |
| Valacyclovir | Valacyclovir Hcl | 56 | 20 |
| Atenolol | Atenolol | 55 | 16 |
| Methocarbamol | Methocarbamol | 53 | 27 |
| Bumetanide | Bumetanide | 52 | 18 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 51 | 17 |
| Clonazepam | Clonazepam | 51 | suppressed |
| Xarelto | Rivaroxaban | 51 | 12 |
| Finasteride | Finasteride | 50 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 48 | 15 |
| Famotidine | Famotidine | 46 | 20 |
| Glipizide | Glipizide | 46 | 18 |
| Propranolol Hcl | Propranolol Hcl | 46 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | 12 |
| Ezetimibe | Ezetimibe | 40 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Estradiol | Estradiol | 39 | 12 |
| Nifedipine Er | Nifedipine | 39 | suppressed |
| Glimepiride | Glimepiride | 38 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 37 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 36 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 24 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 30 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | 12 |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Linzess | Linaclotide | 24 | 11 |
| Lovastatin | Lovastatin | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 21 |
| Promethazine Hcl | Promethazine Hcl | 23 | 11 |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 20 |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Prednisone | Prednisone | 20 | 11 |
| Sucralfate | Sucralfate | 20 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Azithromycin | Azithromycin | 18 | 16 |
| Glipizide Er | Glipizide | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 13 |
| Pentoxifylline | Pentoxifylline | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Zonisamide | Zonisamide | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,080.01 · 59 records | Abbott Laboratories | AIRSUPRA, AUSTEDO XR, CAPVAXIVE, EVENITY, FARXIGA, FREESTYLE LIBRE 3, Flucelvax, INGREZZA, INJECTAFER, INSPIRE, JARDIANCE, Kerendia, Korlym, Leqembi, MOUNJARO, NURTEC ODT, QUTENZA, REPATHA, REXULTI, SYMPLICITY G3, Sunosi, The Cologuard Plus Collection Kit, Tymlos, UBRELVY, VERQUVO, VOQUEZNA, VYNDAQEL, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error